NEW YORK, July 19 - Population genetics company DNA Sciences has withdrawn its initial public offering for $125 million in common stock, according to a filing Thursday with the Securities and Exchange Commission.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.